ImageneBio, Inc.
Moat Score — ImageneBio, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | ImageneBio's core IP is IMG-007, a non-depleting anti-OX40 monoclonal antibody in-licensed from Hutchmed, backed by a genuine proprietary clinical dataset (four completed studies, 150+ dosed subjects, a 54% EASI-75 response at Week 16). This is a real, differentiated technical asset, but it was licensed rather than originated in-house, and milestone/royalty obligations to Hutchmed cap how much of the underlying IP's value ImageneBio ultimately captures. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage company with zero approved products and no owned manufacturing, ImageneBio has no cost structure advantage whatsoever. It relies entirely on third-party CDMOs, principally WuXi Biologics, for drug substance and is a price-taker on development costs just like every other OX40-focused biotech chasing the same mechanism. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | IMG-007 has no approval and generates no product revenue (2025 revenue of ~$0.8M was collaboration/license-related, not drug sales), so there is no current pricing power. Even if approved, IMG-007 would launch into an atopic dermatitis market where Dupixent and other incumbents have already set the price and reimbursement benchmarks, limiting ImageneBio's day-one pricing freedom. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A biologic therapy for atopic dermatitis or alopecia areata carries no network effect — a given patient's or physician's use of IMG-007, if it is ever approved, does not make the drug more valuable to the next patient, unlike a platform or marketplace business model. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | No patients or prescribers currently use IMG-007, so there are no real switching costs today. Post-approval, dermatology and immunology prescribing can exhibit modest habit-based stickiness once a physician sees a drug work in specific patients, but this is a small, mostly unrealized advantage rather than a structural lock-in comparable to embedded enterprise software. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | Atopic dermatitis and adjacent immune-mediated inflammatory disease is an enormous, extremely well-capitalized market (anchored by Dupixent's multi-billion-dollar franchise) crowded with Sanofi, AbbVie, Eli Lilly, Galderma, Pfizer, and several direct OX40/OX40L rivals (Sanofi's amlitelimab, Abcellera, Astria/BioCryst, Apogee). This is the opposite of a naturally scale-limited niche — the market's size invites rather than deters competitive entry, so ImageneBio has no efficient-scale protection. |